Sulfonylurea

Early addition of the insulin sensitizer rosiglitazone (Avandia) in older type 2 diabetic patients previously on submaximal doses of a sulfonylurea reduces disease progression and provides superior glycemic control that is sustained over two years.

A study suggests that sulfonylurea oral diabetes medications may be linked to increased risk of coronary artery spasms.